Guangxi Medical University Cancer Hospital
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China24 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT07566052 | |
| Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, gastroparesis, neoplasm, palsy, pyloric stenosis, stomach disorder | Not yet recruiting | Not applicable | 2026-10-07 | NCT07561073 | |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT05920356 | |
| Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer | Platinum-sensitive Recurrent Ovarian Cancer | Not yet recruiting | Phase 3 | 2026-09-16 | NCT07821606 | |
| Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT07367516 | |
| Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2026-09-11 | NCT06598800 | |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | Recruiting | Phase 2 | 2026-08-27 | NCT06783647 | |
| Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2026-07-09 | NCT07586124 | |
| A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 3 | 2026-06-29 | NCT07673029 | |
| A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-05-19 | NCT06378177 | |
| A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, renal cell carcinoma, skin disorder, skin neoplasm, transitional cell carcinoma, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-11 | NCT05661955 | |
| A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | Advanced Neuroendocrine Carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-03-12 | NCT06157827 | |
| A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. | Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-02-06 | NCT07392736 | |
| A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-02-05 | NCT06574568 | |
| A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 3 | 2026-01-13 | NCT05353257 | |
| Clinical Studies for the Treatment of Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2025-12-18 | NCT06825494 | |
| A Study of YL202 in Selected Patients With Advanced Solid Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, non-small cell lung carcinoma, skin disorder, squamous cell carcinoma | Recruiting | Phase 2 | 2025-11-26 | NCT06107686 | |
| A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma | gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2025-07-30 | NCT06767800 | |
| A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 3 | 2025-04-13 | NCT04974398 | |
| Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-03-24 | NCT06854445 | |
| A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2024-11-20 | NCT06566586 | |
| Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Not yet recruiting | Phase 3 | 2024-06-27 | NCT06475599 | |
| Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Not stated | 2023-02-01 | NCT05707819 | |
| Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 3 | 2021-07-20 | NCT04376866 |